Patents Assigned to Neurex Corporation
-
Patent number: 6423689Abstract: The present invention provides compounds that block calcium channels having the Formula I shown below. The present invention also provides methods of using the compounds of Formula I to treat stroke, cerebral ischemia, head trauma, or epilepsy and to pharmaceutical compositions that contain the compounds of Formula I.Type: GrantFiled: December 16, 1998Date of Patent: July 23, 2002Assignees: Warner-Lambert Company, Neurex CorporationInventors: Richard John Booth, Louis Brogley, Wayne Livingston Cody, David Thomas Connor, Harriet Wall Hamilton, John Xiaoqiang He, Lain-Yen Hu, Leonard Joseph Lescosky, Thomas Charles Malone, Laszlo Nadasdi, Michael Francis Rafferty, Bruce David Roth, Diego F. Silva, Yuntao Song, Balazs G. Szoke, Laszlo Urge
-
Patent number: 5859186Abstract: A method of producing analgesia in nociceptive and neuropathic pain is disclosed. The method includes administering to a subject an omega conopeptide which is characterized by its ability to (a) inhibit electrically stimulated contraction of the guinea pig ileum, and (b) bind selectively to omega conopeptide MVIIA binding sites present in neuronal tissue. Also disclosed are novel omega conotoxin peptides effective in producing analgesia.Type: GrantFiled: July 3, 1996Date of Patent: January 12, 1999Assignee: Neurex CorporationInventors: Alan Justice, Tejinder Singh, Kishor Chandra Gohil, Karen L. Valentino, George P. Miljanich
-
Patent number: 5824645Abstract: A method of producing analgesia in nociceptive and neuropathic pain is disclosed. The method includes administering to a subject an omega conopeptide which is characterized by its ability to (a) inhibit electrically stimulated contraction of the guinea pig ileum, and (b) bind selectively to omega conopeptide MVIIA binding sites present in neuronal tissue. Also disclosed are novel omega conotoxin peptides effective in producing analgesia.Type: GrantFiled: November 1, 1996Date of Patent: October 20, 1998Assignee: Neurex CorporationInventors: Alan Justice, Tejinder Singh, Kishor Chandra Gohil, Karen L. Valentino, George P. Miljanich
-
Patent number: 5795864Abstract: Disclosed are formulations effective to stabilize omega conotoxin peptide preparations at elevated temperatures. Novel omega conopeptides also form part of the invention.Type: GrantFiled: June 27, 1995Date of Patent: August 18, 1998Assignee: Neurex CorporationInventors: Gary Arthur Amstutz, Stephen Scott Bowersox, Kishorchandra Gohil, Peter Isadore Adriaenssens, Ramasharma Kristipati
-
Patent number: 5770690Abstract: Bax-.omega. polynucleotides and polypeptides, and compositions effective to hybridize to Bax-.omega. polynucleotides are disclosed. Also disclosed are methods for altering apoptosis in cells, for promoting cell survival and for identifying compounds capable of affecting the binding of Bax-.omega. to other proteins involved in apoptosis.Type: GrantFiled: March 15, 1996Date of Patent: June 23, 1998Assignee: Neurex CorporationInventors: Catherine Mastroni Bitler, Stephen Scott Bowersox, Roberto Crea, Susan Dunham Demo, William A. Horne, Mei Zhou
-
Patent number: 5587454Abstract: Disclosed are novel omega conotoxin peptides effective in producing analgesia.Type: GrantFiled: April 15, 1993Date of Patent: December 24, 1996Assignee: Neurex CorporationInventors: Alan Justice, Tejinder Singh, Kishor C. Gohil, Karen L. Valentino, George P. Miljanich
-
Patent number: 5559095Abstract: A method and compositions for reducing neuronal damage related to an ischemic condition in a mammalian subject are described. The method includes administration of a voltage-gated calcium channel-blocking compound to the subject, 4-24 hours after the onset of the ischemic condition. Such a calcium channel blocking compound is effective to block norepinephrine release in mammalian CNS neuronal cells and is characterized by specific, high affinity binding to omega-conotoxin MVIIA binding sites. Also disclosed are novel peptide structures useful in the treatment method of the invention.Type: GrantFiled: November 12, 1991Date of Patent: September 24, 1996Assignee: Neurex CorporationInventors: George P. Miljanich, Stephen S. Bowersox, James A. Fox, Karen L. Valentino, Robert S. Bitner, Donald H. Yamashiro
-
Patent number: 5424218Abstract: A partially purified omega conotoxin binding protein is disclosed. The protein, either in partially purified form or in a synaptosomal preparation, is useful in identifying compounds for use in reducing neuronal damage related to an ischemic condition, such as stroke, in a human patient.Type: GrantFiled: November 4, 1993Date of Patent: June 13, 1995Assignee: Neurex CorporationInventors: George P. Miljanich, Robert S. Bitner, Stephen S. Bowersox, James A. Fox, Karen L. Valentino, Donald H. Yamashiro
-
Patent number: 5364842Abstract: A method of producing analgesia and enhancing opiate analgesia is disclosed. The method includes administering TVIA (SNX-185) or MVIIA (SNX-111) omega-conopeptide, or derivative thereof which is characterized by its ability to (a) inhibit voltage-gated calcium channels selectively in neuronal tissue, as evidenced by the peptide's ability to inhibit electrically stimulated contraction of the guinea pig ileum, and (b) bind to omega-conopeptide MVIIA binding sites present in neuronal tissue.Type: GrantFiled: June 23, 1993Date of Patent: November 15, 1994Assignee: Neurex CorporationInventors: Alan Justice, Tejinder Singh, Kishor C. Gohil, Karen L. Valentino
-
Patent number: 5264371Abstract: A partially purified omega conotoxin binding protein is disclosed. The protein, either in partially purified form or in a synaptosomal preparation, is useful in identifying compounds for use in reducing neuronal damage related to an ischemic condition, such as stroke, in a human patient.Type: GrantFiled: March 23, 1992Date of Patent: November 23, 1993Assignee: Neurex CorporationInventors: George P. Miljanich, Robert S. Bitner, Stephen S. Bowersox, James A. Fox, Karen L. Valentino, Donald H. Yamashiro, Makoto Tsubokawa
-
Patent number: 5189020Abstract: A partially purified omega conotoxin binding protein is disclosed. The protein, either in partially purified form or in a synaptosomal preparation, is useful in identifying compounds for use in reducing neuronal damage related to an ischemic condition, such as stroke, in a human patient.Type: GrantFiled: August 2, 1990Date of Patent: February 23, 1993Assignee: Neurex CorporationInventors: George P. Miljanich, Robert S. Bitner, Stephen S. Bowersox, James A. Fox, Karen L. Valentino, Donald H. Yamashiro, Makoto Tsubokawa
-
Patent number: 5169852Abstract: Compounds of formula I are useful for suppressing appetite, and for altering macronutrient preferences, ##STR1## where the R.sub.2 -R.sub.9 substituents are so selected as to meet a defined quantitative structure activity relationship (QSAR) quantity relating to the partition coefficient of the compound, the net charge on the ring nitrogen, and the radical superfdelocalizability at the position-8 ring carbon.Type: GrantFiled: December 14, 1990Date of Patent: December 8, 1992Assignee: Neurex CorporationInventors: Jack D. Barchas, Glen R. Elliott, Peter I. Adriaenssens, Robert S. Bitner, Stephen S. Bowersox
-
Patent number: 5051403Abstract: A method of reducing neuronal damage related to an ischemic condition in a human patient, such as stroke-induced damage, by administration of a binding/inhibitory omega-conotoxin peptide.Type: GrantFiled: November 22, 1989Date of Patent: September 24, 1991Assignee: Neurex CorporationInventors: George P. Miljanich, Robert S. Bitner, Stephen S. Bowersox, James A. Fox, Karen L. Valentino, Donald H. Yamashiro
-
Patent number: 4978669Abstract: Compounds of formula I are useful for suppressing appetite, for altering macronutrient preferences, for suppressing obsessive-compulsive behavior, and for inhibiting cravings and substance abuse: ##STR1## wherein R.sub.1 and R.sub.3 are each independently H, hydroxy-alkyl, alpha-cyanoalkyl, SO.sub.3 H, SO.sub.2 NH.sub.2, or C(O)R, where R is OH, NH.sub.2, lower alkoxy, benzyloxy, or aliphatic amino acyl;R.sub.2 and R.sub.9 are each independently H, lower alkyl, benzyl, succinyl, or C(O)R.sub.4, where R.sub.4 is H, lower alkyl, hydrocarboxy-lower alkylene, or lower alkoxycarboxy-lower alkylene; andR.sub.5, R.sub.6, R.sub.7, and R.sub.8 are each independently H, halo, lower alkyl, hydroxy, lower alkoxy, or two adjacent radicals form methylenedioxy or ethylenedioxy;with the proviso that R.sub.1, R.sub.2, R.sub.3, R.sub.5, R.sub.6, R.sub.7, R.sub.8, and R.sub.9 are not simultaneously H.Type: GrantFiled: June 8, 1989Date of Patent: December 18, 1990Assignee: Neurex CorporationInventors: Jack D. Barchas, Glen R. Elliott, Peter I. Adriaenssens, Robert S. Bitner, Stephen S. Bowersox, Laszlo Nadasdi
-
Patent number: 4971974Abstract: Compositions comprising a compound of formula 1, and optionally a mild stimulant, are effective anorectics, where formula 1 is: ##STR1## and its pharmaceutically acceptable acid-addition salts, wherein X and Y are each independently hydrogen, hydroxy, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, fluoro, chloro, or bromo.These compounds are effective for reducing appetite globally, or at lower dosage, for altering macronutrient preferences and decreasing substance dependence.Type: GrantFiled: June 16, 1988Date of Patent: November 20, 1990Assignee: Neurex CorporationInventors: Talmage Bosin, Robert S. Bitner, Theresa M. Gadbois, Victor C. Yu, Stephen S. Bowersox